Instrument Inactif

Autres langues Amylin Pharmaceuticals LLC

Actions

US0323461089

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

16/07/12	GSK annonce le rachat de Human Genome pour $3,0 milliards	RE
02/07/12	Wall Street termine sans grande tendance après les PMI	RE

Autres langues

09/08/12	Amylin Pharmaceuticals, Inc. : Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin
02/08/12	Bristol Myers Squibb Co. : Bristol-Myers executive charged with insider trading
16/07/12	BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion
16/07/12	GlaxoSmithKline plc : Exclusive: GSK set for Human Genome takeover - sources
15/07/12	GlaxoSmithKline plc : GSK in weekend talks to buy Human Genome: sources
12/07/12	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation
10/07/12	Forest Laboratories, Inc. : Exclusive: Icahn offered to settle with Forest before battle
10/07/12	Exclusive: Icahn offered to settle with Forest before battle
09/07/12	Amylin Pharmaceuticals, Inc. : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc.
07/07/12	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
03/07/12	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
03/07/12	Amylin Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of Amylin Pharmaceuticals, Inc.
02/07/12	SANOFI : Icahn return on Amylin tops 35 percent
02/07/12	Bristol Myers Squibb Co. : Bristol's patent woes persist despite Amylin buy
02/07/12	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation
02/07/12	Amylin Pharmaceuticals, Inc. : Harwood Feffer LLP Announces Investigation of Amylin Pharmaceuticals, Inc.
02/07/12	Amylin Pharmaceuticals, Inc. : Rigrodsky & Long, P.A. Announces Investigation Of Amylin Pharmaceuticals, Inc. Buyout
02/07/12	Amylin Pharmaceuticals, Inc. : Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amylin Pharmaceuticals Inc.
02/07/12	Amylin Pharmaceuticals, Inc. : Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
30/06/12	SANOFI : AstraZeneca hungry to refill medicine cabinet
30/06/12	SANOFI : Bristol-Myers to buy Amylin for about $5.3 billion
25/06/12	Amylin Pharmaceuticals, Inc. : New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose and Triglyceride Levels in Patients with Rare Forms of Lipodystrophy
09/06/12	Amylin Pharmaceuticals, Inc. : SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range
09/06/12	Amylin Pharmaceuticals, Inc. : BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes
04/06/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present Data on BYDUREON™, BYETTA® and SYMLIN® at the American Diabetes Association 2012 Meeting